IMNM
Immunome Inc.
Latest Form 4:Sale$264KbyBarchas Isaac (Director) · filed Aug 12, 2026
Immunome Inc. (IMNM) has 31 SEC Form 4 filings (62 transaction rows) in the rolling window, disclosed by 9 distinct insiders. Most recent filing: Aug 12, 2026.
The most active filer is Director Barchas Isaac with 10 filings. Insiders have net sold $18.0M over the trailing 6 months.
- Industry:Biotechnology
- CEO:Clay Siegall
- Employees:177
- HQ:Bothell, WA, US
- IPO:2020-10-02
Insider Buying
$2.3M
reported purchases (SEC code P)
Insider Selling
$27.2M
reported sales (SEC code S)
Unique Insiders
9
in the rolling window
Market Cap
$3.1B
latest known value
| Source | ||||||
|---|---|---|---|---|---|---|
| Director | Sale | 10,125 | $264K | Aug 12 | SEC ↗ | |
| Director | Sale | 62,291 | $1.6M | Aug 12 | SEC ↗ | |
| Director | Sale | 11,048 | $301K | Aug 12 | SEC ↗ | |
| Director | Sale | 20,840 | $543K | Aug 10 | SEC ↗ | |
| Director | Sale | 15,248 | $397K | Aug 10 | SEC ↗ | |
| CHIEF BUSINESS OFFICER | Sale | 90,616 | $2.3M | Aug 6 | SEC ↗ | |
Horn KinneyFirst filing | CHIEF BUSINESS OFFICER | Sale | 1,092 | $27K | Jul 9 | SEC ↗ |
| Director | Sale | 83,094 | $2.0M | Jul 7 | SEC ↗ | |
| Director | Sale | 16,906 | $409K | Jul 7 | SEC ↗ | |
| Chief Medical Officer | Sale | 55,000 | $1.2M | Jul 7 | SEC ↗ | |
Barchas IsaacFirst in 6 months | Director | Sale | 101,050 | $2.1M | Jul 3 | SEC ↗ |
Barchas IsaacFirst in 6 months | Director | Sale | 100,000 | $2.3M | Jul 3 | SEC ↗ |
Lechleider RobertFirst filing | Chief Medical Officer | Sale | 55,000 | $1.1M | Jun 29 | SEC ↗ |
| Chief Financial Officer | Sale | 60,000 | $1.1M | Jun 17 | SEC ↗ | |
| Director | Sale | 10,500 | $204K | Jun 9 | SEC ↗ | |
| Director | Purchase | 10,500 | $204K | Jun 9 | SEC ↗ | |
| Director | Purchase | 5,000 | $104K | May 19 | SEC ↗ | |
Rosett MaxFirst filing | Chief Financial Officer | Sale | 65,000 | $1.4M | Apr 3 | SEC ↗ |
Higgins JackFirst filing | Chief Scientific Officer | Sale | 9,438 | $204K | Apr 3 | SEC ↗ |
SIEGALL CLAY BFirst in 3 months | President and CEO | Purchase | 25,450 | $501K | Mar 31 | SEC ↗ |
WAGENHEIM PHILIPFirst filing | Director | Sale | 36,800 | $753K | Mar 23 | SEC ↗ |
WAGENHEIM PHILIPFirst filing | Director | Sale | 28,200 | $582K | Mar 23 | SEC ↗ |
| Director | Purchase | 1,000 | $22K | Mar 12 | SEC ↗ | |
| Director | Purchase | 1,000 | $22K | Mar 12 | SEC ↗ | |
| President and CEO | Purchase | 4,729 | $100K | Dec 30 | SEC ↗ | |
Barchas IsaacFirst filing | Director | Sale | 383,200 | $8.3M | Dec 23 | SEC ↗ |
Tsai PhilipFirst filing | Chief Technical Officer | Purchase | 10,000 | $205K | Dec 22 | SEC ↗ |
| President and CEO | Purchase | 7,278 | $149K | Dec 22 | SEC ↗ | |
SIEGALL CLAY BFirst filing | President and CEO | Purchase | 46,511 | $1000K | Dec 18 | SEC ↗ |
Related companies
Immunome Inc. is in the Healthcare sector.